Table 1 Demographics and methods of included clinical trials
Cerza et al., 2012 [22] | Filardo et al., 2012 [11] | Sanchez et al., 2012 [24] | Vaquerizo et al., 2013 [25] | Filardo et al., 2015 [23] | Raeissadat et al., 2015 [13] | Montañez-Heredia, et al. 2016 [14] | |
|---|---|---|---|---|---|---|---|
Registered | Not recorded | Not recorded | Real Decreto 223/2004 | Real Decreto 223/2004 | ClinicalTrials.gov, NCT01670578 | IRCT20140121134 42N5 | ClinicalTrials.gov, NCT02448407 |
Subject enrollment date | September 2009–September 2010 | Not recorded | January 2008–November 2009 | Not recorded | 2009–2013 | Not recorded | January to March 2014 |
Country | Italy | Italy | Spain | Spain | Italy | Iran | Spain |
Conflict of interest | None | None | None | Not mentioned | Not mentioned | None | None |
No. of subjects (knees) | 120 (120) | 109 (109) | 176 (176) | 96 (96) | 183 (183) | 160 (160) | 55 (55) |
Sex: male, female | 53, 67 | 68, 41 | 85, 91 | 38, 58 | 112, 71 | 23, 116 | 21, 32 |
Mean age, yr | 66.4 | 56.5 | 59.8 | 63.6 | 55.34 | 58.79 | 63.9 |
BMI, kg/m2 | Not recorded | 26.5 | 28.0 | 30.9 | 25.7 | 27.68 | 29.7 |
Bilateral vs. unilateral knee injections | Unilateral | Unilateral | Unilateral | Unilateral | Unilateral | Unilateral | Unilateral |
Ultrasound-guided injections or not | Not mentioned | Not mentioned | Not mentioned | Not mentioned | Not mentioned | Not mentioned | No |
Study group 1 | 60 Patients | 54 Patients | 87 Patients | 48 Patients | 96 Patients | 87 Patients | 28 Patients |
Study group 2 | 60 Patients | 55 Patients | 89 Patients | 48 Patients | 96 Patients | 73 Patients | 27 Patients |
Baseline characteristic differences between groups | No differences | No differences | No differences | No differences | No differences except for age | No differences except for age, sex, WOMAC (pain, function) | No differences |
Radiographic classification | Kellgren-Lawrence | Kellgren-Lawrence | Ahlbäck | Kellgren-Lawrence | Kellgren-Lawrence | Kellgren-Lawrence | Kellgren-Lawrence |
Grade I: 25 | Average of grade | Grade I: 87 | Grade II: 32 | Average of grade | Grade I: 6 | Grade I: 7 | |
Grade II: 22 | 2.2 for PRP group and 2.1 for HA group | Grade II: 64 | Grade III: 47 | 2.0 for PRP group and 2.0 for HA group | Grade II: 91 | Grade II: 19 | |
Grade III: 13 | Grade III: 23 | Grade IV: 17 | Grade III: 75 | Grade III: 27 | |||
Grade IV: 28 | |||||||
Length of follow-up | 24 Weeks | 12 Months | 6 Months | 48 Weeks | 12 Months | 52 Weeks | 6 Months |
Outcome scores used | WOMAC | IKDC, Tegner, KOOS, EQ VAS | WOMAC, VAS | WOMAC, Lequesne, OMERACT-OARSI | IKDC, KOOS, EQ VAS, Tegner score | WOMAC, SF-36 | VAS, KOOS, EuroQol |
Prior surgeries | No | 63 Subjects | None in last year | Not recorded | 101 Subjects | Not recorded | No |
Prior injections | No | Not recorded | None in prior 6 months | None in prior 6 months | Conservative | None in prior 2 weeks | No |
PRP no. of injections | 4 | 3 | 3 | 3 | 3 | 2 | 3 |
PRP volume per Injection | 5.5 ml | 8 ml | 12 ml | 8 ml | 5 ml | 4–6 ml | 5 ml |
Injection interval, wk | 1 | 1 | 1 | 2 | 1 | 4 | 2 |
Injection approach | Superolateral | Not recorded | Superolateral | Superolateral | Not recorded | Anteromedial or lateral midpatellar | Not recorded |
Primary and secondary outcomes | WOMAC score before infiltration and at 4, 12, and 24 weeks after first injection | IKDC, EQ VAS, Tegner, and KOOS scores, range of motion and knee circumference changes were evaluated at 2, 6, and 12 months | WOMAC scores at 1, 2, and 6 months | WOMAC and Lequesne scores at 24 and 48 weeks | IKDC, KOOS, EQ VAS, and Tegner scores at baseline and then at 2, 6, and 12 months after last injection | WOMAC and SF-36 scores at 52 weeks | VAS, KOOS, EuroQol following the third infiltration and after 3 and 6 months following final infiltration |